The shift from nGBM to all GBM including rGBM seems pretty clear.
So, checking my understanding here. If reimbursement is tracking with approval, and approval occurs, and I choose DCVax-L treatment I'm reimbursed for the tumor resection and treatment, which includes current SOC (chemo/rad) + DCVax-L. Then if my tumor comes back, for the first time in history there will be an approved treatment for rGBM and instead of palliative care I can be reimbursed for having another resection and another round of DCVax-L -- and, as I understand it based on the trial, I would not have another dose of chemo/rad. Is this right?